CynthiaXiuguangMaMDPh.D.

Clinical Trials

• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Start of enrollment: 2001 Dec 01

  Completed

  Phase 1

• Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction Start of enrollment: 2005 Aug 01

  Completed

  Phase 2

• PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer Start of enrollment: 2006 Mar 01

  Terminated

  Phase 2

• Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells Start of enrollment: 2005 Sep 14

  Recruiting

• Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer Start of enrollment: 2008 Oct 31

  Completed

  Phase 1, Phase 2

• PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations Start of enrollment: 2010 Feb 01

  Completed

  Phase 2

• Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer Start of enrollment: 2010 Jun 30

  Active, not recruiting

  Phase 2

• BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer Start of enrollment: 2011 Nov 14

  Completed

  Phase 1

• MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer Start of enrollment: 2011 Apr 21

  Completed

  Phase 1

• Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2011 May 02

  Active, not recruiting

  Phase 1

• Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer Start of enrollment: 2012 Sep 01

  Withdrawn

  Phase 2

• A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03

  Terminated

  Phase 3

• Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies Start of enrollment: 2013 May 07

  Completed

  Phase 1

• PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer Start of enrollment: 2013 Apr 10

  Active, not recruiting

  Phase 2

• LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Start of enrollment: 2014 Apr 01

  Withdrawn

  Phase 2

• Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer Start of enrollment: 2013 Jan 01

  Terminated

  Phase 2

• Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells Start of enrollment: 2013 Dec 19

  Terminated

  Phase 2

• VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03

  Terminated

  Phase 1, Phase 2

• Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer Start of enrollment: 2014 Aug 01

  Withdrawn

  Phase 2

• Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Start of enrollment: 2013 Dec 13

  Active, not recruiting

  Phase 3

• Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01

  Completed

  Phase 2

• Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity Start of enrollment: 2014 Jul 07

  Terminated

  Phase 2

• Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer Start of enrollment: 2017 Jun 15

  Completed

  Phase 2

• Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer Start of enrollment: 2018 Aug 07

  Withdrawn

  Phase 2

• Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer Start of enrollment: 2020 Jun 17

  Active, not recruiting

  Phase 1, Phase 2

• Join now to see all